SynAct Pharma AB - Asset Resilience Ratio
SynAct Pharma AB (SYNACT) has an Asset Resilience Ratio of 0.13% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SYNACT current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how SynAct Pharma AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of SynAct Pharma AB.
Liquid Assets Composition Over Time
This chart breaks down SynAct Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SYNACT total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr180.00K | 0.13% |
| Total Liquid Assets | Skr180.00K | 0.13% |
Asset Resilience Insights
- Limited Liquidity: SynAct Pharma AB maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SynAct Pharma AB Industry Peers by Asset Resilience Ratio
Compare SynAct Pharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for SynAct Pharma AB (2020–2023)
The table below shows the annual Asset Resilience Ratio data for SynAct Pharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.04% | Skr93.00K ≈ $10.01K |
Skr228.02 Million ≈ $24.54 Million |
-0.09pp |
| 2022-12-31 | 0.13% | Skr180.00K ≈ $19.37K |
Skr142.60 Million ≈ $15.35 Million |
+1.09pp |
| 2020-12-31 | -0.96% | Skr-208.00K ≈ $-22.38K |
Skr21.59 Million ≈ $2.32 Million |
-- |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and id… Read more